1.
Parente DB,
Perez RM,
Eiras-Araujo A,
Oliveira Neto JA,
Marchiori E,
Constantino CP,
Amorim VB,
Rodrigues RS.
MR imaging of hypervascular lesions in the cirrhotic liver: a diagnostic dilemma.
Radiographics 2012; 32(3): 767-787.
2.
Bruix J,
Sherman M.
Management of hepatocellular carcinoma: An update.
Hepatology 2011; 53(3): 1020–1022.
3.
Piana G,Trinquart L,Meskine N,Barrau V,Beers BV,Vilgrain V.NewMRimagingcriteriawith adiffusion-weightedsequencefor thediagnosisofhepatocellular carcinomainchronicliver diseases.J Hepatol 2011; 55(1): 126-132.
4. European Association for the Study of the Liver,
European Organisation for Research and Treatment of Cancer.
EASL–E ORTC clinical practice guidelines: Management of hepatocellular carcinoma.
Journal of Hepatology 2012; 56j; 908–943.
5. Lim KS.
Diffusion-weighted MRI of hepatocellular carcinoma in cirrhosis.
Clin Radiol 2014; 69(1): 1-10.
6. Taouli B,
Koh DM.
Diffusion-weighted MR imaging of the liver.
Radiology 2010; 254(1): 47-66.
7. Xu PJ,
Yan FH,
Wang JH,
Shan Y,
Ji Y,
Chen CZ.
Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
J Comput Assist Tomogr 2010; 34(4): 506-512.
8. Vandecaveye V,
De Keyzer F,
Verslype C,
Op de Beeck K,
Komuta M,
Topal B,
Roebben I,
Bielen D,
Roskams T,
Nevens F,
Dymarkowski S.
Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma.
Eur Radiol 2009; 19(10): 2456-2466.
9. Demir OI,
Obuz F,
Sağol O,
Dicle O.
Contribution of diffusion-weighted MRI to the differential diagnosis of hepatic masses.
Diagn Interv Radiol 2007; 13(2): 81-86.
10. Nasu K,
Kuroki Y,
Tsukamoto T,
Nakajima H,
Mori K,
Minami M.
Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics andrelationship among signal intensity,
apparent diffusion coefficient,
and histopathologic grade.
AJR Am J Roentgenol 2009; 193(2): 438-444.
11. Bolog N,
Andreisek G,
Oancea I,
Mangrau A.
CT and MR imaging of hepatocellular carcinoma.
J Gastrointestin Liver Dis 2011; 20(2): 181-189.
12. Padhani AR,
Liu G,
Koh DM,
Chenevert TL,
Thoeny HC,
Takahara T,
Dzik-Jurasz A,
Ross BD,
Van Cauteren M,
Collins D,
Hammoud DA,
Rustin GJ,
Taouli B,
Choyke PL.
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.
Neoplasia 2009; 11(2): 102-125.
13. Ross BD,
Moffat BA,
Lawrence TS,
Mukherji SK,
Gebarski SS,
Quint DJ,
Johnson TD,
Junck L,
Robertson PL,
Muraszko KM,
Dong Q,
Meyer CR,
Bland PH,
McConville P,
Geng H,
Rehemtulla A,
Chenevert TL.
Evaluation of cancer therapy using diffusion magnetic resonance imaging.
Mol Cancer Ther 2003; 2(6): 581-587.
14. Debruyne EN,
Delanghe JR.
Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications.
Clin Chim Acta 2008; 395(1-2):19-26.
15. Zhao YJ,
Qiang JU,
Guan-Cheng LI.
Tumor markers for hepatocellular carcinoma.
Mol Clin Oncol 2013; 1(4): 593–598.